ETC 1907206

Drug Profile

ETC 1907206

Alternative Names: ETC 206; ETC-1907206

Latest Information Update: 09 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator D3 (Drug Product and Development), Biomedical Sciences Institute
  • Developer D3 (Drug Discovery & Development), Biomedical Sciences Institute
  • Class Antineoplastics
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 01 Feb 2018 Preclinical trials in Acute lymphoblastic leukaemia in Singapore (PO) (Before February 2018) (NCT03414450)
  • 01 Feb 2018 Preclinical trials in Chronic Myeloid leukaemia in Singapore (PO) (Before February 2018) (NCT03414450)
  • 01 Feb 2018 D3 (Drug Discovery and Development), Biomedical Sciences Institute plans a phase I trial for Acute lymphoblastic leukemia and Chronic myeloid leukaemia (Combination therapy, Late-stage disease) in Singapore and USA (NCT03414450)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top